I've asked that question but it's obviously something they can't/won't answer.
Impairments over the past 5 years now total over $1,000,000,000 with not all but the bulk of that attributable to the $880M spent on the Teva generic portfolio.
What is disappointing is that 2019 was the great 'reset' to use Roger Corbett's wording when impairments totalled $350M. The impression given at that time was that $350M should tidy up the balance sheet and be the end of the impairments ........
Intangibles totalled $1235M after the Teva purchase in 2017.
There's been $1056M in impairments since then.
Intangibles now showing $428M.
I've asked that question but it's obviously something they...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.03 |
Change
-0.170(3.27%) |
Mkt cap ! $408.6M | |||
| Open | High | Low | Value | Volume |
| $5.20 | $5.21 | $5.03 | $2.804M | 555.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 14654 | $5.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.14 | 3111 | 2 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| MYX (ASX) Chart |